Cocrystal Pharma, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Cocrystal Pharma, Inc. on March 26, 2019, reporting events occurring between December 14, 2018, and March 21, 2019. The filing addresses changes to the Company's Equity Distribution Agreement regarding the sale of its common stock.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance and financing agreements rather than operational financial performance.
Material Changes
- Termination of Sales Agents: Ladenburg Thalmann & Co. Inc. terminated its engagement as a sales agent on December 14, 2018. Barrington Research Associates, Inc. terminated its engagement on March 21, 2019.
- Amendment to Distribution Agreement: On March 20, 2019, the Company and Alliance Global Partners (AGP) amended the Equity Distribution Agreement originally dated July 19, 2018.
- Continuity of Agreement: The amendment ensures the Distribution Agreement remains valid for AGP despite the termination of the other agents.
- Suspension of Sales: The Company and AGP agreed to suspend sales of the Company's common stock under the agreement until further notice.
Outlook, Risks, and Management Commentary
The filing notes that Barrington was required to act as a "qualified independent underwriter" due to a conflict of interest involving Dr. Phillip Frost, a Company director, who held significant beneficial ownership in both the Company and Ladenburg's parent company. The suspension of stock sales indicates a strategic pause in capital raising activities via this specific mechanism.
Key Facts for Investor Verification
- Verify the current status of the suspension on common stock sales under the amended Distribution Agreement.
- Confirm the remaining capacity and terms of the agreement with Alliance Global Partners (AGP) as the sole sales agent.
- Review the full text of the Amendment (Exhibit 10.1) for any additional covenants or conditions not summarized in the 8-K.
- Assess the impact of the suspended sales on the Company's immediate liquidity and capital raise strategy.